Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)

Diabetes Research and Clinical Practice

Volumn 122, Issue , 2016, Pages 133-140

  Matsuhisa, Munehide ^a   Koyama, Masayoshi ^b   Cheng, Xi ^c   Sumi, Mariko ^b   Riddle, Matthew C ^d   Bolli, Geremia B ^e   Hirose, Takahisa ^f  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Sanofi ^*  (Japan)

^c Sanofi Pasteur   (China)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF PERUGIA   (Italy)

^f TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycaemic control; Hypoglycaemia; Insulin glargine; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADULT; BLOOD; BLOOD GLUCOSE MONITORING; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; JAPAN; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; TIME FACTOR;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; JAPAN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84994553389     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.10.002     Document Type: Article

References (26)

1. [1] Chan, J.C., Gagliardino, J.J., Baik, S.H., et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 32 (2009), 227–233, 10.2337/dc08-0435.
2. [2] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 (1993), 977–986, 10.1056/NEJM199309303291401.
3. [3] Nishimura, R., Izumi, K., Hayashino, Y., et al. A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes—JDCP study 2. Diabetol Int 7 (2016), 4–11, 10.1007/s13340-015-0248-5.
4. [4] Japan Diabetes Society. Treatment guide for diabetes 2012–2013. Available at: < http://www.jds.or.jp/modules/en/index.php?content_id=1. [last accessed 21.04.16].
5. [5] American Diabetes Association, Standards of Medical Care in Diabetes - 2016. 7. Approaches to Glycemic Treatment. Diabetes Care 39 (2016), S52–S59, 10.2337/dc16-S010.
6. [6] Authors, Task Force., Members, Ryden L., Grant, P.J., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087, 10.1093/eurheartj/eht108.
7. [7] Peyrot, M., Barnett, A.H., Meneghini, L.F., Schumm-Draeger, P.M., Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med 29 (2012), 682–689, 10.1111/j.1464-5491.2012.03605.x.
8. [8] Atkinson, M.A., Eisenbarth, G.S., Michels, A.W., Type 1 diabetes. Lancet 383 (2014), 69–82, 10.1016/S0140-6736(13)60591-7.
9. [9] Owens, D.R., Matfin, G., Monnier, L., Basal insulin analogues in the management of diabetes mellitus: what progress have we made?. Diabetes Metab Res Rev 30 (2014), 104–119, 10.1002/dmrr.2469.
10. [10] Bolli, G.B., Andreoli, A.M., Lucidi, P., Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 13:Suppl 1 (2011), S43–S52, 10.1089/dia.2011.0039.
11. −1. Diabetes Care 38 (2015), 637–643, 10.2337/dc14-0006.
12. [12] Shiramoto, M., Eto, T., Irie, S., et al. Single-dose new insulin glargine 300 U/mL provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 17 (2015), 254–260, 10.1111/dom.12415.
13. [13] Riddle, M.C., Bolli, G.B., Zieman, M., et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal and mealtime insulin: glucose and hypoglycemia in a 6-month randomized controlled trial (EDITION I). Diabetes Care 37 (2014), 2755–2762, 10.2337/dc14-0991.
14. [14] Yki-Järvinen, H., Bergenstal, R., Zieman, M., et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 37 (2014), 3235–3243, 10.2337/dc14-0990.
15. [15] Bolli, G.B., Riddle, M.C., Bergenstal, R.M., et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 17 (2015), 386–394, 10.1111/dom.12438.
16. [16] Home, P.D., Bergenstal, R.M., Bolli, G.B., et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 38 (2015), 2217–2225, 10.2337/dc15-0249.
17. [17] Matsuhisa, M., Koyama, M., Cheng, X., et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab 18 (2016), 375–383, 10.1111/dom.12619.
18. [18] Terauchi, Y., Koyama, M., Cheng, X., et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab 18 (2016), 366–374, 10.1111/dom.12618.
19. [19] ICH, ICH harmonized tripartite guideline: Guideline for Good Clinical Practice E6 (R1). 1996.
20. [20] World Medical Association, Declaration of Helsinki. Ethical principles for medical research involving human subjects. 2013.
21. [21] ADA Workgroup on Hypoglycemia, Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28 (2005), 1245–1249 doi.org/10.2337/diacare.28.5.1245.
22. [22] Cryer, P.E., Davis, S.N., Shamoon, H., Hypoglycemia in diabetes. Diabetes Care 26 (2003), 1902–1912, 10.2337/diacare.26.6.1902.
23. [23] Bergenstal, R., Bailey, T., Robard, D., et al. Insulin glargine 300 U/mL vs 100 U/mL: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM). Diabetes Tech Ther 17 (2015), A16–7, 10.1089/dia.2015.1525 (abstract 39).
24. [24] Jinnouchi, H., Koyama, M., Amano, A., et al. Continuous glucose monitoring during basal-bolus therapy using insulin glargine 300 U mL(−1) and glargine 100 U mL (−1) in Japanese people with type 1 diabetes mellitus: a crossover pilot study. Diabetes Ther 6 (2015), 143–152, 10.1007/s13300-015-0115-1.
25. [25] Sanofi, Data on file. 2015.
26. [26] Bolli, G.B., Kerr, D., Thomas, R., et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 32 (2009), 1170–1176, 10.2337/dc08-1874.